A share of Theseus Pharmaceuticals Inc. (NASDAQ:THRX) closed at $9.60 per share on Friday, up from $8.10 day before. While Theseus Pharmaceuticals Inc. has overperformed by 18.52%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, THRX fell by -4.57%, with highs and lows ranging from $15.21 to $4.01, whereas the simple moving average jumped by 34.30% in the last 200 days.
Top 5 Undervalued Stocks To Own In 2023
Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.
Click here to download your Free Research Report…
Sponsored
On December 14, 2022, Needham started tracking Theseus Pharmaceuticals Inc. (NASDAQ: THRX) recommending Buy. A report published by H.C. Wainwright on June 30, 2022, Initiated its previous ‘Buy’ rating for THRX. Wedbush also rated THRX shares as ‘Outperform’, setting a target price of $24 on the company’s shares in an initiating report dated November 01, 2021. SVB Leerink Initiated an Outperform rating on November 01, 2021, and assigned a price target of $28. Jefferies initiated its ‘Buy’ rating for THRX, as published in its report on November 01, 2021. Cantor Fitzgerald’s report from November 01, 2021 suggests a price prediction of $25 for THRX shares, giving the stock a ‘Overweight’ rating.
Analysis of Theseus Pharmaceuticals Inc. (THRX)
Theseus Pharmaceuticals Inc.’s future performance can be predicted by a variety of well-rounded types of analysis and research, with equity being one of the most crucial ones. The goal here is to ensure that your current return on equity of -19.60% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 27.50, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
For any stock, average volume can be an extremely valuable indicator of volatility, and THRX is registering an average volume of 139.67K. On a monthly basis, the volatility of the stock is set at 10.79%, whereas on a weekly basis, it is put at 11.29%, with a gain of 15.66% over the past seven days. Furthermore, long-term investors anticipate a median target price of $21.67, showing growth from the present price of $9.60, which can serve as yet another indication of whether THRX is worth investing in or should be passed over.
How Do You Analyze Theseus Pharmaceuticals Inc. Shares?
Besides checking the fundamentals, you should also know how many employees own shares in the company. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 0.90%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 89.50% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
Are institutional investors increasing their holdings in THRX shares?
The recent increase in stakes in THRX appears to be a result of several institutional investors and hedge funds increasing their positions. Fidelity Management & Research Co’s position in THRX has decreased by -7.33% in the first quarter. The company now owns 4,802,535 shares of the stock, with a value of $23.92 million, following the sale of -380,123 additional shares during the last quarter. T. Rowe Price Associates, Inc. made another decreased to its shares in THRX during the first quarter, downing its stake by -0.27%. During the last quarter, the company picked up -3,794 additional shares for a total stake of worth $6.88 million, bringing number of shares owned by the company to 1,381,489.
During the first quarter, BlackRock Fund Advisors added a 65,723 position in THRX. The Vanguard Group, Inc. sold an additional 3371.0 shares in the last quarter, decreasing its holdings by -0.55%, now holding 0.61 million shares worth $3.05 million. THRX shares are owned by institutional investors to the tune of 89.50% at present.
